The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
This study is designed to assess the effect of the different continuous s.c. infusion
treatments on the human growth hormone (hGH) levels in untreated acromegalic patients in
comparison to a standard dose of octreotide. In addition, the pharmacokinetic profile and the
safety and tolerability of DG3173 after continuous s.c. infusion will be evaluated.